avarol has been researched along with Inflammation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amigó, M; Braza-Boïls, A; De Rosa, S; Payá, M; Terencio, MC | 1 |
| Alcaraz, MJ; Bustos, G; De Rosa, S; Ferrándiz, ML; Payá, M; Sanz, MJ | 1 |
2 other study(ies) available for avarol and Inflammation
| Article | Year |
|---|---|
Avarol inhibits TNF-alpha generation and NF-kappaB activation in human cells and in animal models.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Epidermis; Female; Humans; Hyperplasia; Inflammation; Inflammation Mediators; Keratinocytes; Mice; Monocytes; NF-kappa B p50 Subunit; Peroxidase; Psoriasis; Sesquiterpenes; Tetradecanoylphorbol Acetate; Tumor Necrosis Factor-alpha | 2008 |
Avarol and avarone, two new anti-inflammatory agents of marine origin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Carrageenan; Cyclohexenes; Edema; Indomethacin; Inflammation; Leukocytes; Male; Mice; Peritoneum; Phospholipases A; Phospholipases A2; Rats; Sesquiterpenes; Superoxides; Tetradecanoylphorbol Acetate | 1994 |